Everything tagged "guidance" across the TickerSpark archives.
Foot Locker has shifted from DICK’S growth catalyst to earnings drag, with a $31.9 million operating loss and a projected $40 million to $80 million full-year loss. The 30.68% selloff is rational, and the integration bull case needs to be rebuilt from scratch.
INV's AI-cooling bet no longer has a measurable 2026 commercialization clock: Accelsius suspended its revenue and cash-flow targets after customer-side power, GPU and deployment constraints. With $2.06M of revenue against a $293.32M net loss, the stock now asks investors to fund milestones before it proves conversion.
MAIR delivered a strong Q2, but the raised full-year sales guide was not large enough to justify a 134.81x trailing P/E. We see the selloff as an expectations reset that can continue until backlog converts into faster earnings growth.
A 4%-5% organic growth guide, down from 7%-9%, landed alongside a 9.7% EPS miss and a 23.16% selloff on 3.2x relative volume. With a 105.98x trailing P/E and weak technicals, the post-spin bull case has lost its near-term footing.
Insulet's 20.12% selloff reflects a credibility hit to its U.S. growth engine, not merely a disappointing trading session. The FY2026 guidance cut makes the Omnipod runway harder to underwrite, even after a strong Q2 and continued international expansion.
Boston Scientific’s plunge looks like a real reset, not a bargain-bin overreaction. Management already cut 2026 growth guidance, then reinforced that Watchman weakness is tied to a worsening procedure mix that the market can’t just wave away.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime